GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Single Dose Escalation First Time in Human PK Study

Phase 1

Completed

Conditions: Infections, Bacterial

Interventions: Drug: 800 mg GSK investigational drug
Drug: 3000mg GSK investigational drug
Drug: 100 mg GSK investigational drug
Drug: 200 mg GSK investigational drug
Drug: 400 mg GSK investigational drug
Drug: 1500 mg GSK investigational drug
Drug: 2000 mg GSK investigational drug
Drug: 800mg fed GSK investigational drug
Drug: 4000mg GSK investigational drug

First Posted Date: 2009-01-26

Last Posted Date: 2017-06-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 41

Registration Number: NCT00828867

Locations: 🇦🇺
GSK Investigational Site, Randwick, New South Wales, Australia

Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.

Phase 3

Completed

Conditions: Infections, Streptococcal

Interventions: Biological: Pneumococcal vaccine GSK1024850A
Biological: Tritanrix-HepB/Hib
Biological: measles
Biological: Rotarix
Biological: Local OPV

First Posted Date: 2009-01-26

Last Posted Date: 2018-08-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 489

Registration Number: NCT00829010

Locations: 🇿🇦
GSK Investigational Site, Soweto, Gauteng, South Africa

A Phase 1 Study to Evaluate the Safety and Tolerability of GSK1362885 in Healthy Normal Subjects

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: GSK1362885
Drug: Glucagon
Drug: Glucagon + GSK1362885

First Posted Date: 2009-01-16

Last Posted Date: 2017-07-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 42

Registration Number: NCT00823940

Locations: 🇺🇸
GSK Investigational Site, Minneapolis, Minnesota, United States

Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease

Phase 3

Completed

Conditions: Parkinson Disease

Interventions: Drug: ropinirole PR/XR
Drug: ropinirole IR

First Posted Date: 2009-01-16

Last Posted Date: 2017-01-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 302

Registration Number: NCT00823836

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Phase 2

Completed

Conditions: Lymphoma, Large-Cell, Diffuse

Interventions: Drug: ofatumumab + ICE
Drug: ofatumumab + DHAP

First Posted Date: 2009-01-16

Last Posted Date: 2013-03-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 61

Registration Number: NCT00823719

Allergen Challenge Chamber Study With Single Dose Intranasal GSK1004723 Compared With Placebo

Phase 2

Completed

Conditions: Allergic Rhinitis

Interventions: Drug: GSK1004723 (1000mg)
Other: Placebo
Drug: GSK1004723 (200mg)

First Posted Date: 2009-01-16

Last Posted Date: 2009-06-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 54

Registration Number: NCT00824356

Locations: 🇩🇪
GSK Investigational Site, Hannover, Niedersachsen, Germany

A Study to Examine the Effects of Low and High-fat Meals on Orally Administered Lapatinib in Metastatic ErbB2 Positive Breast Cancer Patients

Phase 1

Completed

Conditions: Neoplasms, Breast

Interventions: Drug: Lapatinib

First Posted Date: 2009-01-12

Last Posted Date: 2017-11-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 24

Registration Number: NCT00821054

Locations: 🇳🇱
GSK Investigational Site, Amsterdam, Netherlands

Study of Lapatinib in Breast Cancer Patients With HER-2 Non-amplified Primary Tumors and HER-2 Positive or EGFR Positive Circulating Tumor Cells

Phase 2

Terminated

Conditions: Neoplasms, Breast

Interventions: Drug: LAPATINIB

First Posted Date: 2009-01-12

Last Posted Date: 2012-03-28

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 23

Registration Number: NCT00820924

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

An Open Label Positron Emission Tomography (PET) Study of GSK618334 in Healthy Male Subjects Using 11C-PHNO as PET Ligand

Phase 1

Completed

Conditions: Substance Dependence

Interventions: Drug: GSK618334

First Posted Date: 2008-12-25

Last Posted Date: 2017-07-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 12

Registration Number: NCT00814957

Locations: 🇬🇧
GSK Investigational Site, Harrow, Middlesex, United Kingdom

Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 10 Weeks of Age

Phase 3

Completed

Conditions: Streptococcus Pneumoniae
Infections, Streptococcal

Interventions: Biological: Pneumococcal conjugate vaccine GSK1024850A
Biological: Hiberix
Biological: Tritanrix-HepB/Hib
Biological: Tritanrix-HepB

First Posted Date: 2008-12-25

Last Posted Date: 2020-01-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 360

Registration Number: NCT00814710

Locations: 🇮🇳
GSK Investigational Site, Vellore, India

Home Terms & Conditions Privacy Policy